Staff

TOP 5 publications:

1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Frölich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease.N Engl J Med. 2023 388(1):9-21. Epub 2022 Nov 29.
2. Jessen F, Frölich L, Hort J, Winblad B, Fortea J. Amyloid-lowering treatment in Alzheimer's disease.Lancet. 2024 404(10468):2161-2162. Epub 2024 Nov 14.
3. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Frölich L, Alzheimer Genetic Analysis Group . TREM2 variants in Alzheimer's disease.N Engl J Med. 2013 368(2):117-27.
4. Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.JAMA. 2018 319(2):130-142.
5. Heilmann S, Drichel D, Clarimón J, Fernández V, Lacour A, Wagner H, Thelen M, Hernández I, Fortea J, Alegret M, Blesa R, Mauleón A, Roca MR, Kornhuber J, Peters O, Heun R, Frölich L, Hüll M, Heneka MT, Rüther E, Riedel-Heller S, Scherer M, Wiltfang J, Jessen F, Becker T, Tárraga L, Boada M, Maier W, Lleo A, Ruiz A, Nöthen MM, Ramirez A. PLD3 in non-familial Alzheimer's disease.Nature. 2015 520(7545):E3-5.